Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 7, 2009, Pages 1226-1229

  Faramarzi, Negar ^a   Abbasi, Ata ^a   Tavangar, Seyed M ^b   Mazouchi, Marjan ^a   Dehpour, Ahmad R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Cholestasis; Endogenous opioids

Indexed keywords

ANTIBODY; NALTREXONE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CHOLESTASIS; CONTROLLED STUDY; LIVER; MALE; MICROSCOPY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; TISSUE SECTION;

EID: 68749119965     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05794.x     Document Type: Article

References (24)

1. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int. J. Biochem. Cell Biol. 2006 38 : 333 57.
2. Chaparro M Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann. Hepatol. 2007 6 : 208 13.
3. Lai WK, Adams DH. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J. Hepatol. 2005 42 : 7 11.
4. Das SK, Vasudevan DM. Essential factors associated with hepatic angiogenesis. Life Sci. 2007 81 : 1555 64.
5. Rosmorduc O, Wendum D, Corpechot C et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol. 1999 155 : 1065 73.
6. Gehring S, Dickson EM, San Martin ME et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 2006 130 : 810 22.
7. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992 103 : 630 5.
8. Swain MG, MacArthur L, Vergalla J, Jones EA. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. Am. J. Physiol. 1994 266 : G201 5.
9. Swain MG. Alterations in hypothalamic mu-opiate receptor-mediated responses but not methionine enkephalin or proenkephalin messenger RNA levels in rats with acute cholestasis. Hepatology 1994 20 : 700 5.
10. Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996 16 : 298 302.
11. Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002 22 : 107 13.
12. Blebea J, Mazo JE, Kihara TK et al. Opioid growth factor modulates angiogenesis. J. Vasc. Surg. 2000 32 : 364 73.
13. Balasubramanian S, Ramakrishnan S, Charboneau R, Wang J, Barke RA, Roy S. Morphine sulfate inhibits hypoxia-induced vascular endothelial growth factor expression in endothelial cells and cardiac myocytes. J. Mol. Cell Cardiol. 2001 33 : 2179 87.
14. Pasi A, Qu BX, Steiner R, Senn HJ, Bar W, Messiha FS. Angiogenesis: modulation with opioids. Gen. Pharmacol. 1991 22 : 1077 9.
15. Gupta K, Kshirsagar S, Chang L et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002 62 : 4491 8.
16. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J et al. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc. Res. 2006 72 : 3 11.
17. Ma Z, Zhang Y, Huet PM, Lee SS. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. J. Hepatol. 1999 30 : 485 91.
18. Kiani S, Ebrahimkhani MR, Shariftabrizi A et al. Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis. J. Gastroenterol. Hepatol. 2007 22 : 406 13.
19. Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J. Hepatol. 2005 42 : 124 31.
20. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997 113 : 1264 9.
21. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J. Hepatol. 2002 37 : 717 22.
22. Mansour-Ghanaei F, Taheri A, Froutan H et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J. Gastroenterol. 2006 12 : 1125 8.
23. Ebrahimkhani MR, Kiani S, Oakley F et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006 55 : 1606 16.
24. Payabvash S, Kiumehr S, Nezami BG et al. Endogenous opioids modulate hepatocyte apoptosis in a rat model of chronic cholestasis: the role of oxidative stress. Liver Int. 2007 27 : 538 47.